Coronavirus vaccine for children likely to be approved soon: Sources

A decision on the booster is expected to take some time

vaccine
As of now India has only ZyCoV-D, the DNA vaccine for Covid-19 from Zydus Cadila approved for children above 12 years
Sohini Das Mumbai
2 min read Last Updated : Dec 21 2021 | 12:43 PM IST
The Coronavirus (Covid-19) vaccine for children is likely to be approved soon, sources said, adding that the decision on the booster shot may take some time.

“Vaccination for children is likely to start in phases, and an approval on the same is expected  as schools have started to open,” said a government official close to the development. He further added that vaccines for children might be opened up in phases, first for vulnerable children and those above 12 years.

A final decision, however, will be taken by the National Technical Advisory Group on Immunisation (NTAGI).

In a meeting held earlier this month, the NTAGI had deliberated both on whether to give a booster dose to people who are immuno-compromised like cancer patients etc, and children. A decision is still pending.

An industry source also said that a decision on children's vaccination is expected soon. “It is expected anytime now. And in January we expect that vaccination for children will be opened,” the source said.

As of now India has only ZyCoV-D, the DNA vaccine for Covid-19 from Zydus Cadila approved for children above 12 years. Bharat Biotech’s Covaxin has received the nod from the subject expert committee for use in children above 2 years, but the drug regulator is yet to approve the same.

In a recent interview, Shahid Jameel, presently a Senior Research Fellow at Green Templeton College at Oxford University, said that delaying immediate boosters could result in 5 per cent more deaths than expected.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineVaccination

Next Story